REFRACTORY FOLLICULAR LYMPHOMA

This early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…

This study is for people with follicular lymphoma that has come back or not responded to treatment. It compares new experimental therapies to the current standard care to see which works better. About 284 adults will take part, and the main goal is to see if the new treatments ca…

This phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has returned or not responded to prior therapies. About 22 adults with grade 1-3a lymphoma will receive the combination. The goal is to improve cancer remissio…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…